Kyverna Therapeutics, Inc. Stockholders Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Class Action Against KYTX

SAN DIEGO, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) and certain of the Company's senior executives and directors who signed the Registration Statement, effective February 7, 2024, issued in connection with the Company's initial public offering ("IPO"). Kyverna is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. For mo ...